Whole Live Micro-organism, Cell, Or Virus Containing Patents (Class 424/93.1)
  • Patent number: 10758655
    Abstract: This document discusses, among other things, systems and methods to reduce ischemic or metabolic injury to a patient's heart. A system to reduce ischemic or metabolic injury to a patient's heart may include a pulse generator for generating electrical pulses or shock, a pacing lead with at least one pacing electrode configured to deliver electrical pulses received from the pulse generator to the patient's heart, a controller configured to control timing of electrical pulses to reduce wall stress of the heart, and a reservoir, fluidically coupled to a lumen and a pump, wherein the pump is configured, under control of the controller, to move contents from the reservoir through the lumen to an area of the heart with the reduced wall stress, wherein the contents include autologous respiration-competent mitochondria or other respiratory-promoting agents.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 1, 2020
    Assignee: Cardiac Pacemakers, Inc.
    Inventors: Barbara Ann Huibregtse, Thomas John Herbst, Craig Stolen, Eric M. Schneider, Lynne E. Swanson, Lili Liu
  • Patent number: 10736922
    Abstract: Disclosed are isolated human bone marrow mesenchymal stem cells having high telomerase activity (tBMMSCs). Also disclosed are isolated human CD34+ bone marrow mesenchymal stem cells. Also disclosed are bone marrow mesenchymal stem cells treated with a telomerase induction agent.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 11, 2020
    Assignee: University of Southern California
    Inventors: Songtao Shi, Kentaro Akiyama, Chider Chen
  • Patent number: 10731136
    Abstract: The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or ongogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 4, 2020
    Inventor: Per Sonne Holm
  • Patent number: 10695404
    Abstract: Methods of using FGF1 analogs, such as FGF1 mutant proteins having an N-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1-binding protein, a ?-Klotho-binding protein and a FGFR1-binding protein, a C-terminal region from FGF19 or FGF21.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: June 30, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu
  • Patent number: 10688151
    Abstract: The invention relates to a peptide, polypeptide, or protein that binds specifically to cells of the lung endothelium. The peptide, polypeptide, or protein can be a component of a viral capsid and can be used to lead a recombinant viral vector selectively to the lung endothelial tissue after systemic administration to a subject and to ensure tissue-specific expression of one or more transgenes there. The invention thus further relates to a recombinant viral vector, preferably an AAV vector, which comprises a capsid comprising the peptide, polypeptide, or protein according to the invention and which comprises at least one transgene packaged in the capsid. The viral vector is suitable in particular for the therapeutic treatment of a lung disorder or a lung disease. The invention further relates to cells and pharmaceutical compositions which comprise the viral vector according to the invention.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: June 23, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Trepel, Jakob Koerbelin, Stefan Michelfelder
  • Patent number: 10676747
    Abstract: An active agent capable of reducing quinone reductase 2 activity is for use in improvement of cognition in a subject. Such an active agent can be a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 or an inhibitor of quinone reductase 2 activity. A pharmaceutical composition can contain the active agent or a vector containing the active agent.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: June 9, 2020
    Assignee: CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD.
    Inventors: Kobi Rosenblum, Akiva Rappaport
  • Patent number: 10669526
    Abstract: The present disclosure relates to stem cells derived from a pure chorionic trophoblast layer (chorionic trophoblast layer without villi, CT-V), which is a part of the tissues of the placenta, and cell therapy comprising same. Stem cells derived from a pure chorionic trophoblast layer according to the present invention exhibit uniform growth characteristic, and superb proliferation and differentiation characteristics compared to the conventional stem cells derived from the whole placenta, and particularly, exhibit excellent differentiation into cartilage cells, thus can be effectively used in cell therapy for treating cartilage damage, deficiency and such, and as a composition for tissue regeneration.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: June 2, 2020
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Chul Won Ha, Jin A. Kim
  • Patent number: 10639336
    Abstract: The present invention provides a composition for preventing stroke and ameliorating the severity of stroke and comprises an effective dose of Lactobacillus reuteri GMNL-89 and Lactobacillus paracasei GMNL-133; the accession number of Lactobacillus reuteri GMNL-89 is CCTCC M207154 and the accession number of Lactobacillus paracasei GMNL-133 is CCTCC M2011331. The composition can be taken as a dietary supplement and be given continuously after a stroke, and said composition has the effects of ameliorating cerebral infarction, motor function, and intestinal microbiota after a stroke.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: May 5, 2020
    Assignee: GENMONT BIOTECH INCORPORATION
    Inventors: Yi-Hsing Chen, Wan-Hua Tsai, Shiang-Suo Huang, Yi-Hsin Wang
  • Patent number: 10640750
    Abstract: The present invention is directed to methods of inducing spatial organization of cells an in vitro culture system using ultrasound technology. The invention is further directed to methods of inducing extracellular matrix remodeling and neovessel formation in an in vitro culture system and generating vascularized engineered tissue constructs using ultrasound technology.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: May 5, 2020
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Diane Dalecki, Denise Hocking, Kelley Garvin
  • Patent number: 10631974
    Abstract: The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 28, 2020
    Assignee: AVITA MEDICAL LTD
    Inventors: Fiona M. Wood, Marie L. Stoner
  • Patent number: 10613084
    Abstract: Herein is provided a method that provides a patient, suspected of having Lyme disease, a kit that does not require specialized equipment and allows for easy self-collection of specimens. Methods provided herein, allow for the efficient culturing of Borrelia spirochetes, such as B. burgdorferi spirochetes after being exposed to an environment that is typically not suitable for Borrelia growth.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 7, 2020
    Inventors: Marianne Middelveen, Raphael Stricker
  • Patent number: 10584355
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 10, 2020
    Assignees: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 10583220
    Abstract: A biocompatible, bioresorbable tissue repair implant or scaffold device is provided for use in repairing a variety of cartilage tissue injuries, and particularly for resurfacing and/or repairing damaged or diseased cartilage. The repair procedures may be conducted with tissue repair implants that contain a biological component that assists in delaying or arresting the progression of degenerative joint diseases and in enhancing tissue healing or repair. The biocompatible, bioresorbable tissue repair implants include a scaffold and particles of viable tissue derived from cartilage tissue, such that the tissue and the scaffold become associated. The particles of living tissue contain one or more viable cells that can migrate from the tissue and populate the scaffold.
    Type: Grant
    Filed: August 11, 2003
    Date of Patent: March 10, 2020
    Assignee: DePuy Synthes Products, Inc.
    Inventors: Francois Binette, Ed Yiling Lu
  • Patent number: 10576106
    Abstract: The present disclosure relates to a novel musculoskeletal stem cell (MSSC) differentiated from an ESC (embryonic stem cell) or an iPSC (induced pluripotent stem cell). The musculoskeletal stem cell of the present disclosure can be easily induced from a human embryonic stem cell or a human-derived pluripotent stem cell and can be effectively differentiated not only into bone but also into cartilage, tendon and muscle. Accordingly, it can be usefully used for prevention or treatment of various musculoskeletal diseases.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: March 3, 2020
    Assignee: Cellatoz Therapeutics, Inc.
    Inventor: Myung-Kwan Han
  • Patent number: 10563226
    Abstract: Disclosed herein are nuclease-based systems for genome editing and methods of using the system for genome editing. Also, disclosed are approaches to enhance Cas9-mediated gene editing efficiency in primary human cells with minimal toxicity when using adeno-associated virus vectors (AAV) to express the guide RNAs necessary for CRISPR/Cas9-based genome editing in the presence of helper proteins.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: February 18, 2020
    Assignee: Seattle Children's Hospital
    Inventors: Andrew Scharenberg, David Rawlings, Michael C. Jensen, Kamila Gwiazda, Alexandra Grier
  • Patent number: 10538742
    Abstract: This invention relates to the methods for the identification and isolation of cancer stem cells from cultured cancer cell lines. Cell line-derived cancer stem cells isolated using the present methods may be useful, for example, in assays to screen compounds for anti-cancer stem cell activity and in target discovery methods for identifying novel expressed genes and druggable targets. The invention also relates to the screening of compounds for activity against cell line-derived cancer stem cells.
    Type: Grant
    Filed: November 12, 2005
    Date of Patent: January 21, 2020
    Assignee: Cambridge Enterprise Limited
    Inventor: Toru Kondo
  • Patent number: 10526577
    Abstract: Disclosed are genetically modified human pancreatic progenitor cells having an exogenous nucleic acid molecule encoding TGIF2, for use as a medicament in the treatment of a subject with diabetes. In addition methods for the production of such cells are described. Also disclosed is an expression vector encoding TGIF2 for use as a medicament in the treatment of a subject with diabetes.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: January 7, 2020
    Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN
    Inventors: Francesca Spagnoli, Nuria Cerda-Esteban
  • Patent number: 10514163
    Abstract: The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: December 24, 2019
    Assignee: PROPAGENIX INC.
    Inventor: Chengkang Zhang
  • Patent number: 10507225
    Abstract: The present disclosure relates to the field of health care products. The present disclosure provides a powder which is prepared from xylooligosaccharide, isomaltooligosaccharide, mannitol, inulin, RADIX CODONOPSIS, FRUIT BODY HERICIUM ERINACEUS extract, RHIZOMA DIOSCOREA OPPOSITA, SCLEROTIUM PORIA, SEMEN DOLICHOS, PERICARPIUM CITRUS, FRUCTUS AMOMUM and RHIZOMA MACROCEPHALA. All raw materials are from natural Chinese herbal medicine. No additives are added. The method for preparing the powder in the present disclosure is simple and suitable for large-scale production. Also, it is easy to be carried. Experiment data shows that the powder described in the present disclosure has the function of relieving the gastric mucosal injury by reducing the acute gastric mucosal injury induced by ethanol effectively and has the function of regulating gastric mucosa.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: December 17, 2019
    Assignee: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Lei Wang, Ruiqi He, Hongwei Zhao, Qingtao Tang
  • Patent number: 10501756
    Abstract: The present invention relates to a gene therapy vector which is useful in the treatment or prevention of hypertrophic cardiomyopathy in a subject in need thereof. The gene therapy vector of the invention comprises a nucleic acid sequence encoding a cardiac sarcomeric protein and a cardiomyocyte-specific promoter which is operably linked to said nucleic acid sequence. The invention furthermore relates to a cell which comprises the gene therapy vector. Pharmaceutical compositions which comprise the gene therapy vector and/or a cell comprising said vector are also provided. In another aspect, the invention relates to a method for treating or preventing hypertrophic cardiomyopathy in a subject by introducing the gene therapy vector of the invention into a subject in need of treatment.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: December 10, 2019
    Assignees: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG, SORBONNE UNIVERSITÉ, ASSOCIATION INSTITUTE DE MYOLOGIE
    Inventors: Lucie Carrier, Thomas Eschenhagen, Thomas Voit, Giulia Mearini, Oliver Mueller, Doreen Stimpel, Julia Mourot-Filiatre
  • Patent number: 10494607
    Abstract: Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45? stem cells from placenta.
    Type: Grant
    Filed: February 12, 2008
    Date of Patent: December 3, 2019
    Assignee: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Marian Pereira, Sascha Dawn Abramson, Kristen S. Labazzo
  • Patent number: 10493104
    Abstract: The present invention relates to a composition for treating inflammatory brain diseases which includes a stem cell as an active ingredient. When the stem cell according to the present invention is directly administered to animal models with inflammatory brain diseases, a brain damage caused by inflammation such as edema is significantly reduced, the weight-loss phenomenon is greatly improved, and the like, and thus the cell has an excellent effect in treating inflammatory brain diseases and consequently can be used effectively in treating inflammatory brain diseases.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: December 3, 2019
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Yun Sil Chang, Won Soon Park
  • Patent number: 10464994
    Abstract: Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: November 5, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Yong-Jian Geng
  • Patent number: 10443106
    Abstract: The invention relates to methods and compositions for identifying specific bacterial species, which are sulfur and iron oxidizers and/or reducers, from wall board (e.g., dry wall) and/or a patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the bacterial species from the wall board and/or the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the bacterial species, and specifically identifying the bacterial species. Kits and nucleic acids for use in the methods are also provided. Methods for eliminating the sulfur and iron oxidizing and/or reducing bacteria from wall board using a zeolite are also provided.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: October 15, 2019
    Assignee: Advatect Diagnostics, LLC
    Inventor: Dennis G. Hooper
  • Patent number: 10435732
    Abstract: The present invention provides a method for producing a recombinant protein, which can increase the cell growth rate in culture while stably maintaining plasmids in the cells, thereby improving the recombinant protein yield. The present invention provides a method for producing a recombinant protein, including a high-temperature culture step of culturing at 32° C. or higher a Brevibacillus bacterium that contains a gene encoding a recombinant protein, and a low-temperature culture step of culturing the Brevibacillus bacterium at a temperature lower than 32° C. after the high-temperature culture step.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: October 8, 2019
    Assignee: KANEKA CORPORATION
    Inventors: Hiroyuki Kanamaru, Teruaki Takesue, Osamu Odawara, Takeyuki Tsuchidate
  • Patent number: 10426826
    Abstract: The present invention relates to a Shigella strain, of which the surface exposure of a protective antigen existing on a cellular membrane is increased due to the destruction of a wzy gene of Shigella sp., and to a vaccine composition for treating or preventing shigellosis, containing the mutant Shigella strain as an active ingredient. The Shigella strain of the present invention has a cell wall with a reduced thickness since a gene encoding a protein necessary for polymerization of the O-saccharide antigen is deleted, and as a result, membrane antigens including protein antigens commonly existing in different Shigella spp. are more exposed to immune cells, and thus the Shigella strain can be favorably used as a vaccine composition for treating or preventing shigellosis, derived from various Shigella spp.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: October 1, 2019
    Assignee: International Vaccine Institute
    Inventors: Jae Ouk Kim, Min Jung Kim, Man Ki Song
  • Patent number: 10392632
    Abstract: This application relates to the fields of gene therapy and molecular biology. In accordance with the present invention, an adeno-associated virus (AAV) vector comprising an altered capsid protein is provided. More specifically, this invention provides adeno-associated viral vectors comprising protein capsid variants which accelerate vector breakdown and clearance, thereby reducing undesirable immune responses.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: August 27, 2019
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: John Fraser Wright, Olga Zelenaia, Bernd Hauck, Federico Mingozzi, Katherine A. High
  • Patent number: 10369254
    Abstract: The invention provides for a device, system, and methods for using the same with kidney progenitor cells, specifically ureteric bud (UB) cells, metanephric mesenchymal (MM) cells, and the stromal cell (SC) subpopulation of the metanephric mesenchyme, to generate an embryonic kidney organoid that can be implanted into a mammalian subject to create a living, functional kidney.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 6, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, U.S. DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Norimoto Yanagawa, Masaki Nishikawa, Morgan Hamon, Peter Viktor Hauser
  • Patent number: 10344073
    Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: July 9, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Abraham Rutenberg, Ronny Uzana, Michal Lotem, Arthur Machlenkin, Galit Eisenberg, Tamar Peretz-Yablonsky, Shoshana Frankenburg, Roni Engelstein
  • Patent number: 10332286
    Abstract: Systems and methods are described that provide a dynamic reporting functionality that can identify important information and dynamically present a report about the important information that highlights important findings to the user. The described systems and methods are generally described in the field of diabetes management, but are applicable to other medical reports as well. In one implementation, the dynamic reports are based on available data and devices. For example, useless sections of the report, such as those with no populated data, may be removed, minimized in importance, assigned a lower priority, or the like.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 25, 2019
    Assignee: DexCom, Inc.
    Inventors: Georgios Zamanakos, Daniel Justin Wiedeback, Jeffrey Grant Stewart, Eli Reihman, David Price, Lauren C. Miller, Keri Leone, Dan Kraemer, Katherine Eng Kirby, Greg Kida, Apurv Ullas Kamath, Adam R. Greene, Rebecca Gimenez, Sarah Paige Elli, Rian Draeger, Shane Philip Delmore, Leif N. Bowman
  • Patent number: 10287641
    Abstract: The invention relates to new isolated Lactobacillus strains chosen from Lactobacillus mellifer Bin4N.sup.T (LMG P-28344) and Lactobacillus apinorum Fhon13N.sup.T (LMG P-28345), which have been isolated from honeybees or their processed food. The bacterial strains have unique properties such as production of benzene, free fatty acids and 2-heptanone, rendering them useful in many areas such as in food and beverage products, feed products and medical products.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: May 14, 2019
    Assignee: CONCELLAE AB
    Inventors: Tobias Olofsson, Alejandra Vasquez
  • Patent number: 10286009
    Abstract: The present disclosure provides methods and compositions for making and using pluripotent stem cell-derived oligodendrocyte progenitor cells.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: May 14, 2019
    Assignee: Asterias Biotherapeutics, Inc.
    Inventors: Edward D. Wirth, III, Jane S. Lebkowski
  • Patent number: 10272102
    Abstract: The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of a hematological neoplasm, especially by effectively reducing proliferation rate of cancer cells and inhibiting cancer cell growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: April 30, 2019
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Martin Westphal, Silke Baasner
  • Patent number: 10232000
    Abstract: The present disclosure relates to stem cells derived from the basal portion of the chorionic trophoblast layer (bCT), which is a part of the issues of the placenta, and cell therapy comprising same. Stem cells derived from the basal portion of the chorionic trophoblast layer according to the present invention exhibit uniform growth characteristic, and superb proliferation and differentiation characteristic as compared with the conventional stem cells derived from the full placenta or other tissues, and exhibit excellent tissue regeneration effect in an animal model, thus can be effectively used in cell therapy.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: March 19, 2019
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Chul Won Ha, Jin A. Kim
  • Patent number: 10227567
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: March 12, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
  • Patent number: 10214751
    Abstract: The present invention provides a method for treatment of biomass material by fermentation, said method comprises a pre-treatment of the biomass material by thermal hydrolysis and wet explosion, resulting in an intermediate product having a dry matter concentration above 25% and temperature above 90° C. which is to be introduced to the fermentation, wherein a part of the content of the digestion tank used for the fermentation is recirculated and mixed with a part of the intermediate product from the pre-treatment.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: February 26, 2019
    Assignee: CAMBI TECHNOLOGY AS
    Inventors: Paal Jahre Nilsen, Hans Rasmus Holte
  • Patent number: 10189955
    Abstract: A nested capsule having a first capsule held within a second capsule. Each of the first and second capsules has a shell that is a supramolecular cross-linked network, such as a cucurbituril supramolecular cross-linked network. Each capsule shell is obtained or is obtainable from the complexation of a composition including a host, such as cucurbituril, and one or more building blocks having suitable guest functionality for the host, thereby to form a supramolecular cross-linked network. The nested capsules are suitable for delivering and selectively releasing an encapsulant at a location.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: January 29, 2019
    Assignee: CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Jing Zhang, Roger Coulston, Richard Parker, Christopher Abell, Oren Scherman, Ziyi Yu
  • Patent number: 10179918
    Abstract: Methods and compositions for increasing transgene expression and/or activity, including for increasing nuclease-mediated genomic modifications.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 15, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Gregory J. Cost
  • Patent number: 10166261
    Abstract: The present invention discloses the use of probiotics for therapeutic management of major depressive disorder (MDD). Specifically, the invention discloses the method of therapeutically managing MDD in mammals with Irritable bowel syndrome using probiotic strain Bacillus coagulans MTCC 5856.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 1, 2019
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali
  • Patent number: 10160955
    Abstract: A method of generating one of podocyte progenitor cells and neural stem/progenitor cells comprising the steps of collecting a urine specimen from a patient; centrifuging the urine specimen; and removing the one of podocyte progenitor cells and neural stem/progenitor cells.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 25, 2018
    Assignee: Board of Supervisors of Louisiana State University
    Inventor: Yuping Wang
  • Patent number: 10123517
    Abstract: Immunocompetent animal models having immunological tolerance to a xenograft and methods of producing the same. The animal models are tolerized to the xenograft in the pre-immune, fetal or embryonic stage, followed by transplanting the xenograft into the animal in the post-natal stage, such that the post-natal animal is immunologically tolerant to the xenograft, while remaining immunocompetent.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 13, 2018
    Assignee: Kansas State University Research Foundation
    Inventors: Deryl Troyer, Duane Davis, Stefan Bossmann
  • Patent number: 10119123
    Abstract: The present invention relates to the reprogramming of differentiated somatic cells, such as those differentiated cells that arise from embryonic mesoderm, into glial cells. Glial cells produced from this reprogramming are functionally equivalent to glial cells that arise from ectodermal origins.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: November 6, 2018
    Assignee: Case Western Reserve University
    Inventors: Paul J. Tesar, Robert H. Miller, Fadi J. Najm
  • Patent number: 10114008
    Abstract: Disclosed are methods and systems for testing the effects of various morphogens and/or feeder cells on the differentiation of pluripotent cells. The assays described herein can be used for determining the optimum conditions that lead to differentiation of stem cells. Once the optimum conditions for stem cell differentiation are determined, such cells may be used in a variety of therapies.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: October 30, 2018
    Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventor: Yansong Gu
  • Patent number: 10111821
    Abstract: Methods are disclosed for administering electromagnetic radiation (EMR), which may include filtering EMR from part of the EMR spectrum while allowing passage of EMR at a desired wavelength range. Uses may include the treatment of such conditions as psoriasis, vitiligo, pruritus, acne, vitamin-D deficiency and atopic dermatitis. Topical creams, sprays, or other compositions may be used, with or without dosimeters, or in conjunction with an application, which calculates local UV exposure and other factors relating to dosage.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: October 30, 2018
    Assignee: Applied Biology, Inc.
    Inventors: Andy Ofer Goren, John McCoy
  • Patent number: 10098847
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 16, 2018
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
  • Patent number: 10077426
    Abstract: The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (GVHD) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: September 18, 2018
    Assignee: Enlivex Therapeutics Ltd
    Inventors: Dror Mevorach, Inna Reiner
  • Patent number: 10071149
    Abstract: The present invention is related to various vaccine compositions against Bordetella avium and methods for preparing and administering the various vaccine compositions. The present invention is related to multivalent vaccines compositions such as bivalent or trivalent vaccines for inoculating turkeys against from Bordetella avium rhinotracheitis or coryza due to Bordetella avium infection as well as methods of preparing and administering the multivalent vaccine compositions.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: September 11, 2018
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Marcus M. Jensen, Richard A. Robison
  • Patent number: 10066215
    Abstract: Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: September 4, 2018
    Assignee: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Kyuhyun Lee, Seongtae Yun, Daekyung Koh, Hong-Kyu Lee, Eui-Cheol Jo
  • Patent number: 10064931
    Abstract: Nucleic acid molecules which encode an MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed. Compositions comprising the nucleic acid molecules are disclosed. Novel proteins which comprise a MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed are disclosed. Methods of inducing an immune response against MRSA PBP2a are disclosed, as are methods of treating an individual who has been diagnosed with MRSA and methods of preventing MRSA infection in an individual.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: September 4, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Matthew P. Morrow
  • Patent number: 10059923
    Abstract: The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: August 28, 2018
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Johannes L. Zakrzewski, Marcel R. M. Van Den Brink, Michel Sadelain